Article navigation

Introduction: Fournier gangrene (FG) is a rare, life-threatening condition of the genital, perineal, scrotal, and abdominal regions. Common risk factors include male sex, diabetes, and advanced age. Mortality ranges from 5 to 20% or higher. The main treatment approach is surgical debridement with empirical antibiotics. This study examines the microbiological spectrum in relation to diabetes, age, infection parameters, and clinical outcomes. Methods: We conducted a single-center retrospective analysis of 50 FG patients between 2012 and 2023. The microbiological spectrum was analyzed in relation to age, diabetes, infection parameters, intensive care unit (ICU) stay, and mortality using multinomial logistic regression. The most frequent pathogens were identified, and an autoregressive integrated moving average (ARIMA) model was used to assess potential temporal shifts in pathogen prevalence. AI tools were used in the writing of this manuscript. The principles of the Helsinki Declaration were followed. Results: The median age of the male cohort was 68.5 years (interquartile ranges [IQRs], 68.5–76). Diabetes was present in 20/50 (40%). Infection parameters at admission were 17 mg/L (IQR 8–29.2) for C-reactive protein and 14.8 × 109/L (IQR 11.6–21.1) for leukocyte count. Thirty-two (64%) patients required ICU treatment after surgery. The median ICU stay was 4.5 days (IQR 2–9), and the median hospitalization was 12 days (IQR 8–22). Mortality was 14% (7/50). The microbiological spectrum was unaffected by infection parameters or age. Diabetes, however, was significantly associated with anaerobic pathogens (RRR: 8.0; 95% CI: 1.17–54.7). ARIMA analysis showed no temporal shift in pathogens. Conclusion: Diabetes mellitus is a significant risk factor for FG, promoting infection via microangiopathy, glucosuria, and hyperglycemia-induced tissue hypoxia. Management requires urgent debridement and broad-spectrum antibiotics, with extended anaerobic coverage in diabetic patients.

1.
Furr
J
,
Watts
T
,
Street
R
,
Cross
B
,
Slobodov
G
,
Patel
S
.
Contemporary trends in the inpatient management of fournier’s gangrene: predictors of length of stay and mortality based on population-based sample
.
Urology
.
2017
;
102
:
79
84
.
2.
Kim
SY
,
Dupree
JM
,
Le
BV
,
Kim
DY
,
Zhao
LC
,
Kundu
SD
.
A contemporary analysis of fournier gangrene using the National Surgical Quality improvement Program
.
Urology
.
2015
;
85
(
5
):
1052
7
.
3.
Sorensen
MD
,
Krieger
JN
.
Fournier’s gangrene: epidemiology and outcomes in the general US population
.
Urol Int
.
2016
;
97
(
3
):
249
59
.
4.
Shet
P
,
Mustafa
AD
,
Varshney
K
,
Rao
L
,
Sawdagar
S
,
McLennan
F
, et al
.
Risk factors for mortality among patients with fournier gangrene: a systematic review
.
Surg Infect
.
2024
;
25
(
4
):
261
71
.
5.
Li
L
,
Rysavy
MA
,
Bobashev
G
,
Das
A
.
Comparing methods for risk prediction of multicategory outcomes: dichotomized logistic regression vs. multinomial logit regression
.
BMC Med Res Methodol
.
2024
;
24
(
1
):
261
.
6.
Helfenstein
U
.
Box-Jenkins modelling in medical research
.
Stat Methods Med Res
.
1996
;
5
(
1
):
3
22
.
7.
Thwaini
A
,
Khan
A
,
Malik
A
,
Cherian
J
,
Barua
J
,
Shergill
I
, et al
.
Fournier’s gangrene and its emergency management
.
Postgrad Med J
.
2006
;
82
(
970
):
516
9
.
8.
Yilmazlar
T
,
Gulcu
B
,
Isik
O
,
Ozturk
E
.
Microbiological aspects of Fournier’s gangrene
.
Int J Surg
.
2017
;
40
:
135
8
.
9.
Lim
ZLT
,
Liu
Y
,
Chan
KJ
,
Kim
JJY
,
Chung
E
.
Fournier gangrene microbiology and risk factors
.
J Surg
.
2025
;
10
:
11263
.
10.
Goldney
J
,
Sargeant
JA
,
Davies
MJ
.
Incretins and microvascular complications of diabetes: neuropathy, nephropathy, retinopathy and microangiopathy
.
Diabetologia
.
2023
;
66
(
10
):
1832
45
.
11.
Madonna
R
,
Balistreri
CR
,
Geng
YJ
,
De Caterina
R
.
Diabetic microangiopathy: pathogenetic insights and novel therapeutic approaches
.
Vascul Pharmacol
.
2017
;
90
:
1
7
.
12.
Ljungberg
C
,
Kristensen
FPB
,
Dalager-Pedersen
M
,
Vandenbroucke-Grauls
C
,
Sørensen
HT
,
Nørgaard
M
, et al
.
Risk of urogenital infections in people with type 2 diabetes initiating SGLT2is versus GLP-1RAs in routine clinical care: a Danish cohort Study
.
Diabetes Care
.
2025
;
48
(
6
):
945
54
.
13.
Alexander
M
,
Cho
E
,
Gliozheni
E
,
Salem
Y
,
Cheung
J
,
Ichii
H
.
Pathology of diabetes-induced immune dysfunction
.
Int J Mol Sci
.
2024
;
25
(
13
):
7105
.
14.
Janssen
AWM
,
Stienstra
R
,
Jaeger
M
,
van Gool
AJ
,
Joosten
LA
,
Netea
MG
, et al
.
Understanding the increased risk of infections in diabetes: innate and adaptive immune responses in type 1 diabetes
.
Metabolism
.
2021
;
121
:
154795
.
15.
Atilla
A
,
Temocin
F
,
Kuruoğlu
T
,
Kamalı-Polat
A
.
Fournier’s gangrene: microbiological profile and risk factors for mortality: review of 97 cases
.
Infect Dis Clin Microbiol
.
2023
;
5
(
1
):
13
22
.
16.
Tang
LM
,
Su
YJ
,
Lai
YC
.
The evaluation of microbiology and prognosis of fournier’s gangrene in past five years
.
SpringerPlus
.
2015
;
4
(
1
):
14
.
17.
Chennamsetty
A
,
Khourdaji
I
,
Burks
F
,
Killinger
KA
.
Contemporary diagnosis and management of Fournier’s gangrene
.
Ther Adv Urol
.
2015
;
7
(
4
):
203
15
.
You do not currently have access to this content.
Don't already have an account? Register

Digital Version

Pay-Per-View Access
$45.00
Rental

or Create an Account

Close Modal
Close Modal